Gradient Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Gradient Health provides a medical imaging data platform giving AI researchers and healthcare companies access to de-identified radiology datasets for model training and validation.
About
Gradient Health is a healthcare data company founded in 2019 that operates a platform providing access to de-identified medical imaging data for AI development, research, and regulatory validation. The company partners with health systems and imaging centers to source, de-identify, and structure radiology datasets including X-rays, CT scans, MRI studies, and pathology images that AI developers need to train and validate clinical algorithms. Obtaining sufficient high-quality labeled medical imaging data has been one of the primary bottlenecks for AI medical imaging companies, and Gradient Health addresses this by creating a market for compliant data access. The company uses advanced de-identification techniques that go beyond HIPAA minimum requirements to ensure patient privacy while preserving the clinical detail that makes datasets useful for AI training. Gradient serves medical imaging AI companies, pharmaceutical companies conducting imaging biomarker research, and academic medical centers building AI models. The company has built relationships with health systems across the US and has assembled imaging datasets spanning millions of studies across diverse patient populations and imaging equipment types.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.